Aladar Szalay Sells 48,683 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 48,683 shares of Genelux stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $3.53, for a total value of $171,850.99. Following the sale, the insider now directly owns 1,322,862 shares in the company, valued at approximately $4,669,702.86. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Genelux Stock Performance

NASDAQ GNLX opened at $4.13 on Friday. The business has a 50 day simple moving average of $6.16 and a two-hundred day simple moving average of $11.50. Genelux Co. has a 1-year low of $3.42 and a 1-year high of $40.98.

Wall Street Analysts Forecast Growth

GNLX has been the topic of several recent analyst reports. Benchmark reissued a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a research note on Wednesday, April 3rd. HC Wainwright decreased their target price on Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd.

Hedge Funds Weigh In On Genelux

Several institutional investors have recently added to or reduced their stakes in GNLX. Tower Research Capital LLC TRC purchased a new position in Genelux during the 1st quarter valued at approximately $32,000. Citigroup Inc. purchased a new position in shares of Genelux in the 1st quarter worth approximately $84,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Genelux in the 1st quarter worth approximately $421,000. BlackRock Inc. purchased a new position in shares of Genelux in the 1st quarter worth approximately $402,000. Finally, Geode Capital Management LLC purchased a new position in shares of Genelux in the 1st quarter worth approximately $1,046,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.